Clinical Remission During Extended Follow-Up in Clinically Diagnosed Adult T-Cell Leukemia/Lymphoma Treated with Chemotherapy, Zidovudine, Interferon-Alpha, and Mogamulizumab: A Case Report
Reports · 2026-11-07 · 9 (4) · 381
DOI: 10.3390/reports9040381 ↗Abstract
Background and Clinical Significance: Adult T-cell leukemia/lymphoma (ATLL) is an aggressive mature T-cell malignancy associated with human T-lymphotropic virus type 1 (HTLV-1) and generally has poor outcomes in its acute form. Case Presentation: A 39-year-old woman originally from Jamaica presented with leukocytosis greater than 100 × 109/L, hypercalcemia, lymphadenopathy, splenomegaly, lytic osseous lesions, and multilobulated “flower cells.” Peripheral-blood flow cytometry identified an abnormal T-cell population comprising approximately 85% of events and expressing CD2, cytoplasmic CD3, CD4, CD5, CD25, bright CD15, and HLA-DR, with loss of surface CD3, CD7, CD8, and other markers. Marrow flow cytometry detected approximately 2% atypical T cells. The clinicopathologic findings supported acute ATLL; however, only a reactive HTLV-I/II screening result was available. HTLV-1-specific confirmation, proviral quantification, and clonal proviral integration analysis were not documented. Cerebrospinal fluid later contained an aberrant T-cell population. The treatment record documented one cycle each of EPOCH, Hyper-CVAD, and CHOEP. Formal response assessments and the reasons for each treatment change were unavailable. Zidovudine plus interferon-alpha began in October 2022. CHOEP was administered on 26 October 2022, and mogamulizumab was initiated on 28 October 2022, precluding independent assessment of the CHOEP response. A January 2023 marrow summary stated that no abnormal cells were seen, although the assessment method and specimen adequacy were not specified. At 41 months after diagnosis, the oncology summary described the patient as being in remission without allogeneic stem-cell transplantation. Conclusions: This case describes clinical remission during extended follow-up after overlapping multimodal therapy. It does not establish refractoriness to each chemotherapy regimen, the contribution of any individual treatment, additive or synergistic benefit, optimal treatment sequencing, or the duration of remission.
EUVIMED